Altimmune, Inc. (ALT) — Stock Score Summary

Altimmune, Inc. (ALT) has a MoatMap StockRank of 5/100 based on Quality (31/100), Value (39/100), and Momentum (13/100) factor scores. The current signal is STRONG SELL. Altimmune is a clinical-stage biopharmaceutical company developing obesity drug pemvidutide. While the GLP-1 market is massive, Altimmune is a late entrant with high trial risk and no commercial infrastructure, failing our quality compounder test.

Altimmune, Inc. is a clinical-stage biopharmaceutical company dedicated to developing novel peptide-based therapeutics for chronic diseases, with a primary focus on obesity and liver diseases. The company's pipeline includes differentiated candidates like pemvidutide, a GLP-1/glucagon receptor dual agonist, aiming to address significant unmet medical needs. Its competitive value is intrinsically tied to the clinical efficacy and market potential of its proprietary drug candidates.

Key Financial Metrics

Price$2.66
Market Cap$597M
P/E (Forward)-3.24
Price/Book1.34
Return on Equity-42.7%
Return on Invested Capital-32.9%
Debt/Equity12.62
Gross Margin0.0%
Operating Margin-267247.2%
Free Cash Flow$-43M

Altimmune, Inc. operates in the Biotechnology industry, part of the Healthcare sector (United States).

Frequently Asked Questions

What is Altimmune, Inc.’s (ALT) StockRank?
MoatMap’s StockRank for Altimmune, Inc. (ALT) is 5/100, with a Strong Sell signal. It is a composite of Quality (31), Value (39), and Momentum (13) factor ranks across MoatMap’s 19,000+ stock universe.
Does Altimmune, Inc. have an economic moat?
Altimmune, Inc. (ALT) has a Quality factor score of 31/100. The Quality factor combines ROIC, Piotroski F-Score, and leverage — the financial fingerprints of a durable competitive advantage. A Quality score above 70 typically indicates a company with the characteristics of a moated business.
Is Altimmune, Inc. a buy, hold, or sell?
MoatMap’s current signal for Altimmune, Inc. (ALT) is Strong Sell, based on a StockRank of 5/100. Signals are derived mechanically from the StockRank composite and should be one input among many — combine with your own thesis on management, competitive position, and valuation.
What sector is Altimmune, Inc. in?
Altimmune, Inc. (ALT) operates in the Healthcare sector, specifically the Biotechnology industry (United States).
Browse all ranked stocksALT deep dive reportAI ChampionsHow we score stocksSense-check another stock